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Implantable Cardioverter-Defibrillator Therapy
for Primary Prevention of Sudden Death After
Alcohol Septal Ablation of Hypertrophic Cardiomyopathy
Frank A. Cuoco, MD, William H. Spencer III, MD, Valerian L. Fernandes, MD,
Christopher D. Nielsen, MD, Sherif Nagueh, MD, J. Lacy Sturdivant, MD, Robert B. Leman, MD,
J. Marcus Wharton, MD, Michael R. Gold, MD, PHD
Charleston, South Carolina
Objectives The purpose of this study was to examine the effects of alcohol septal ablation (ASA) on ventricular arrhythmias
among patients with obstructive hypertrophic cardiomyopathy (HCM), as measured by appropriate implantable
cardioverter-defibrillator (ICD) discharges.
Background Alcohol septal ablation is an effective therapy for patients with symptomatic HCM. However, concern has been
raised that ASA may be proarrhythmic secondary to the iatrogenic scar created during the procedure. The im-
pact of ASA on ventricular arrhythmias has not been well described.
Methods This prospective study included 123 consecutive patients with obstructive HCM who underwent ASA and had an
ICD implanted for primary prevention of sudden cardiac death (SCD). The ICDs were implanted based on com-
monly accepted risk factors for SCD in the HCM population. Data from ICD interrogations during routine
follow-up were collected.
Results Nine appropriate ICD shocks were recorded over a mean follow-up of 2.9 years in the cohort, which had a mean
of 1.5  0.9 risk factors for SCD. Using Kaplan-Meier survival analysis, the estimated annual event rate was
2.8% over 3-year follow-up. There were no significant differences in the incidence of risk factors between pa-
tients who did and did not receive appropriate shocks.
Conclusions The annual rate of appropriate ICD discharges after ASA is low and less than that reported previously for primary pre-
vention of SCD in HCM. This suggests that ASA is not proarrhythmic. Traditional SCD risk factors did not predict ICD
shocks in this cohort. (J Am Coll Cardiol 2008;52:1718–23) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.061a
a
O
s
i
r
fl
o
l
m
p
i
A
M
Pypertrophic cardiomyopathy (HCM) is associated with sig-
ificant morbidity, and it is one of the leading causes of sudden
eath under the age of 35 years (1–6). Traditionally, surgical
yectomy is used to relieve outflow tract obstruction and
mprove symptoms in this population (7–12). More recently,
lcohol septal ablation (ASA) has become an increasingly
ommon nonsurgical treatment for obstructive HCM. This
rocedure results in an iatrogenic myocardial infarction, which
n turn decreases septal thickness and systolic anterior motion
SAM) of the mitral valve, reducing resting and provocable left
entricular outflow tract (LVOT) gradients (13–18). It is an
ffective treatment for the symptoms of obstruction, resulting
n decreased angina, reduced heart failure symptoms, and
mproved exercise tolerance (18).
rom the Medical University of South Carolina, Charleston, South Carolina.p
Manuscript received April 21, 2008; revised manuscript received July 7, 2008,
ccepted July 23, 2008.Despite the clear benefit of ASA on the symptoms
ssociated with HCM, the effects of this procedure on the
rrhythmia substrate for sudden death remain controversial.
n one hand, the septal myocardial infarction could be a
ubstrate for ventricular tachyarrhythmias and increase the
ncidence of sudden death (19). On the other hand, the
emodeling that occurs after ASA with reductions of out-
ow tract gradient and septal thickness could reduce the risk
f sudden death (20). Despite this controversy, there are no
arge studies evaluating the risk of life-threatening arrhyth-
ias or sudden death in HCM after ASA. Accordingly, the
resent study was a prospective long-term evaluation of
mplantable cardioverter-defibrillator (ICD) therapy after
SA.
ethods
atient eligibility. This study included 123 consecutive
atients undergoing ASA for symptomatic HCM who had
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November 18, 2008:1718–23 ICD Therapy After Alcohol Ablation for HCMn ICD for primary prevention of sudden cardiac death
SCD) at either the Medical University of South Carolina
r Baylor College of Medicine. The criteria for selection of
atients for ASA were reported previously (16). All patients
igned a written informed consent form, and this study was
pproved by the local institutional review boards.
The ICDs were implanted for the primary prevention of
CD based on commonly accepted risk factors. These risk
actors included: 1) a family history of SCD in a first-degree
elative; 2) a history of syncope or near-syncope not ex-
lained by other mechanisms; 3) an abnormal blood pres-
ure response during exercise treadmill test (a failure to
ncrease systolic blood pressure by20 mm Hg during peak
xercise using a Bruce protocol); and 4) marked septal
ypertrophy (septal thickness 3 cm). The decision for
CD implantation was left to the clinical discretion of the
rimary physician. Patients were excluded from the study if
hey had a history of SCD, sustained ventricular arrhyth-
ias (before study enrollment), or appropriate ICD therapy
efore their ASA. To minimize the risk of selection bias,
nly those patients with an ICD implanted before ASA or
uring the procedural hospitalization were included.
SA procedure. The details of the ablation procedure have
een described in previous reports. Briefly, the septal arterial
ranches supplying the septal bulge were identified with the
ssistance of contrast echocardiography. Between 1 and 3 ml
thanol was used in each septal branch. Gradients across the
VOT were measured before and after ethanol injection,
nd initial success was defined as a decrease in LVOT
radient at rest by 50% as measured by Doppler echocar-
iography or catheter immediately after the procedure.
dditional septal branches were targeted if initial success
as not achieved. A temporary pacemaker in the right
entricular apex was used in all patients who did not have a
ermanent pacemaker or ICD, and was removed if there
as no evidence of high-grade atrioventricular (AV) block
fter ASA. If high-grade AV block did occur, the temporary
acemaker remained in place until baseline conduction
eturned or a permanent pacemaker was implanted. Of note,
CD implantation was only performed if patients were at
isk for sudden death by clinical criteria as described above,
ot for the treatment of heart block. The ICD program-
ing was left to the discretion of the implanting physician,
ut in general only shock therapy was used to treat ventric-
lar tachyarrhythmias and not antitachycardia pacing.
CD follow-up. The patient follow-up period began im-
ediately after ASA and ICD implantation. The ICD data
ere collected during routine follow-up visits (every 3 to 6
onths). The ICD shocks were verified by 2 investigators,
nd deemed appropriate if they treated an episode of
entricular tachycardia (VT) or ventricular fibrillation (VF).
ual-chamber stored electrograms were available in all
atients to facilitate the interpretation of events. For survival
nalysis, follow-up was censured at the time of first appro-
riate ICD therapy. Inappropriate therapies (attributable to
apidly conducted atrial fibrillation, sinus tachycardia, or cther causes) were noted, but
ere not an end point in this
tudy.
tatistical methods. Data are
xpressed as a mean SD. Con-
inuous variables were compared
sing the Student t test, whereas
ategorical variables were ana-
yzed using the Fisher exact test.
urvival analysis for shock-free
urvival was performed using the
aplan-Meier method. A p value
0.05 was considered statisti-
ally significant. Survival analysis
nd statistical calculations were
erformed using the GraphPad
rism software package (Graph-
ad Software, Inc., San Diego,
alifornia).
esults
ata from all 123 consecutive
ubjects with HCM undergoing
SA were collected and available for analysis. Ten patients
8.1%) had at least 1 repeat ASA, and 1 had a total of 3
eptal ablation procedures. The ICD implantation was
erformed after the ASA procedure in 87 patients (70.7%),
hereas the remaining 36 patients underwent implantation
efore the initial procedure (802  853 days). All patients
eceived dual-chamber devices (right atrium, right ventric-
lar apex) to allow for atrial based pacing, if needed.
aseline characteristics. Table 1 compares the baseline
haracteristics of the patients in this study who underwent
SA and had an ICD implanted for primary prevention
ith a similar cohort of consecutive patients who underwent
SA at the Medical University of South Carolina but did
ot receive ICDs. The baseline characteristics and data from
he ASA procedures for the study population are summa-
ized in Table 2. The mean age of the ICD cohort was 48 
5 years, and 81 patients (66%) were male. The subjects had
omparison of Baseline Characteristics inatients Wh Underwent ASA and Re eived anCD for Primary Pr ve tion With a Non-ICD Cohort
Table 1
Comparison of Baseline Characteristics in
Patients Who Underwent ASA and Received an
ICD for Primary Prevention With a Non-ICD Cohort
Non-ICD Cohort
(n  284)
ICD Cohort
(n  123) p Value
Age (yrs) 53 16 48 15 0.003
Gender (male/female) 146/138 81/42 0.009
Resting gradient before ASA (mm Hg) 66 37 61 36 0.237
Resting gradient after ASA (mm Hg) 7 12 14 11 0.001
Septal thickness (cm) 2.1 0.5 2.2 0.5 0.079
Risk factors for SCD 1.1 0.9 1.5 0.9 0.001
alues are mean  SD.
Abbreviations
and Acronyms
ASA  alcohol septal
ablation
AV  atrioventricular
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LVH  left ventricular
hypertrophy
LVOT  left ventricular
outflow tract
NSVT  nonsustained
ventricular tachycardia
SAM  systolic anterior
motion
SCD  sudden cardiac
death
VF  ventricular fibrillation
VT  ventricular
tachycardiaASA  alcohol septal ablation; ICD  implantable ca
ardiac death.rdioverter-defibrillator; SCD  sudden
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ICD Therapy After Alcohol Ablation for HCM November 18, 2008:1718–23mean septal thickness of 2.2  0.5 cm and 1.5  0.9
raditional risk factors for SCD.
CD shocks. The combined total follow-up from this
tudy was 363 patient-years, with a mean follow-up of 2.9
.2 years. Appropriate ICD discharges for ventricular ar-
hythmias occurred in 9 patients over this period. Two
atients (22%) had rapid, monomorphic VT as the rhythm
hat triggered ICD discharge, whereas the remainder had
olymorphic VT or VF. There were no statistically signif-
cant differences in the baseline characteristics of the group
ho did and did not have appropriate ICD shocks (Table 3).
oreover, the presence of multiple risk factors also did not
redict appropriate ICD shocks (3 of 9 vs. 56 of 114,
 0.49). However, the group who did receive shocks had
lower resting LVOT gradient both immediately after ASA
nd at 3- to 12-month follow-up. Using Kaplan-Meier
urvival analysis, the estimated event rate was 2.8% annually.
igure 1 illustrates the shock-free survival curve of this
ohort.
iscussion
his is the first large study to evaluate the long-term risk of
entricular tachyarrhythmias, as measured by appropriate
CD shocks, in a high-risk cohort after ASA. The primary
ndings are that sustained ventricular arrhythmias are un-
ommon after ASA given the low rate of appropriate ICD
hocks in this population. The shock-free survival rate of
90% at 3 years compares favorably with other studies of
CM, suggesting that the ASA procedure does not in-
rease the risk of ventricular tachyarrhythmias.
Baseline Characteristics of the ICD Cohort
Table 2 Baseline Characteristics of the ICD
Age
Male/female
Septal thickness
Resting gradient before ASA (mm Hg)
Resting gradient after ASA (mm Hg)
Resting gradient at 3- to 12-month follow-up (mm Hg)
Peak creatine phosphokinase after ASA
Values are mean  SD.
ASA  alcohol septal ablation.
isk Factors for Sudden Cardiac Death
Table 3 Risk Factors for Sudden Cardiac Death
All
(n  123)
Shock
(n  9)
No Shock
(n  114) p Value
Septum 3 13 (10.5%) 0 (0%) 13 (11.4%) 0.595
Syncope 78 (63%) 5 (56%) 73 (64%) 0.723
Family history of SCD 47 (38%) 4 (44%) 43 (38%) 0.73
Abnormal blood pressure on
exercise treadmill test
42 (46%) 3 (38%) 39 (47%) 0.721
2 risk factors for SCD 59 3 56 0.4946CD  sudden cardiac death.The concern of proarrhythmia after ASA comes from the
bservation that the septal scar produced may be arrhyth-
ogenic (19). Ventricular arrhythmias, predominantly non-
ustained ventricular tachycardia (NSVT), have been noted
n several series during the immediate post-intervention
eriod (16,21). In addition, sustained ventricular arrhyth-
ias (VT/VF) were noted early post-ASA in a few case
eports (21–26). Moreover, in a recently published study
hat reported on the use of ICDs for preventing SCD in a
arge group of patients with HCM (27), the small number
f patients who had prior ASA (n  17) had a 4-fold
ncrease in appropriate ICD intervention rate compared
ith those who underwent surgical myectomy (10.4%/year
s. 2.6%/year, respectively).
echanisms of ventricular arrhythmias after ASA. Pa-
ients with HCM are at increased risk of developing
entricular arrhythmias, most frequently complex premature
entricular complexes, couplets, and NSVT (27–29). Stable,
ustained monomorphic VT is rarely observed among pa-
ients with HCM. Polymorphic VT and/or VF are the most
ommon sustained ventricular arrhythmias in this popula-
ion (28). It is speculated that these disorganized rhythms
ay predominate secondary to the myocardial fiber disarray
hat occurs on a histological level in HCM (30,31). Addi-
Figure 1 Appropriate Shock-Free Survival
Kaplan-Meier curve for shock-free survival in patients after alcohol septal ablation.
rt
ll
123)
Shock
(n  9)
No Shock
(n  114) p Value
.0 55.3 47.5 0.13
42 5/4 76/38 0.49
.19 2.04 2.21 0.38
 36 51 53 62 34 0.55
 11 5 6 15 11 0.014
 22 7 8 22 22 0.001
 671 1,682 1,502 1,130 545 0.3Coho
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November 18, 2008:1718–23 ICD Therapy After Alcohol Ablation for HCMionally, some investigators have suggested that LVOT
bstruction itself is an independent risk factor for SCD and
ppropriate ICD discharges (32). It has been postulated that
n iatrogenic scar could create a substrate for re-entry after
SA (5,19); however, unlike scar caused by ischemic
yocardial infarction secondary to coronary artery disease,
car secondary to ethanol infusion via a septal artery may be
ess arrhythmogenic for several reasons. First, histological
ndings show less pronounced infiltration of connective
issue into the infarcted myocardium (21). Second, the size
f the infarct is generally small:10% of myocardial mass as
easured by cardiac magnetic resonance imaging (33). The
ize of myocardial scar using nuclear perfusion imaging has
een shown to be a significant predictor of inducibility of
T/VF at electrophysiology study (34). Third, ASA leads
o regression of left ventricular hypertrophy (LVH) (20) and
eduction in the LVOT gradient (13–18), which may have
beneficial effect given that the risk of SCD in HCM
ncreases with the magnitude of LVH (35) as well as the
egree of LVOT obstruction (32). Fourth, the patients
ndergoing ASA from this and other studies generally have
o associated coronary artery disease, which can be a cause
f VT/VF (13–17). Finally, LV ejection fraction is perhaps
he most important factor in determining risk for develop-
ng VT/VF after myocardial infarction, and ASA does not
esult in a significant reduction of LV function, as assessed
sing multiple modalities (18,21,32,33,36,37).
CD shocks and ventricular arrhythmias post-myectomy.
n a recently published report of 125 patients with ob-
tructive HCM who underwent ICD implantation (38),
he group who underwent surgical septal myectomy
n  56) had over 10-fold fewer appropriate ICD dis-
harges compared with the nonmyectomy cohort (0.24% vs.
.3% annually, respectively, p 0.004). The investigators of
his report speculate that this lower event rate may be
ttributable to a decrease in LVH, as well as to a decrease in
icrovascular dysfunction resulting from the decrease in
VOT obstruction and associated improvements in regional
yocardial perfusion. Although this cohort included pa-
ients who underwent implantation for both primary as well
s secondary prevention of SCD, their findings are consis-
ent with those in our cohort; that is, the reduction in LVH
nd LVOT gradient associated with septal reduction pro-
edures may offset any proarrhythmic effects from an iatro-
enic scar created during these procedures. Additionally, the
act that the ICD discharge rate in the post-myectomy
roup was lower than that of the ASA group in this study
ay suggest that the types of scars created by these 2
rocedures are fundamentally different. Finally, assuming
hat the risk factor profile in the post-myectomy cohort is
imilar to the cohort in this study, surgical myectomy may
e more effective than ASA in reducing ventricular arrhyth-
ias and ICD shocks; however, direct comparison of these
ohorts is uncontrolled and retrospective observation that
eeds to be confirmed with further studies such as a sandomized, prospective study to draw any definitive
onclusions.
CD shocks and ventricular arrhythmias post-ASA.
here are few data regarding the incidence of ventricular
rrhythmias beyond the immediate post-procedural period
fter ASA. In one series of 39 patients, programmed
entricular stimulation was performed before and 2 weeks
fter ASA; 60% of these patients had a repeat electrophys-
ology study at 7 months post-procedure as well (21). These
nvestigators showed that there was actually a nonsignificant
ecrease in inducibility of VT/VF after the procedure.
dditionally, the event-free survival in this group was 100%
ver a 15-month follow-up period. In a series of 50 patients
ho underwent ASA (21), 2 patients developed VF in the
mmediate post-procedure setting, but no patients devel-
ped sustained ventricular arrhythmias after 48 h out from
heir procedure. In another study, 9 patients who underwent
SA were followed up with serial Holter monitors at 3, 7,
nd 90 days after their intervention (23), and no ventricular
rrhythmias were found with the exception of isolated
remature ventricular complexes. A 1-year follow-up of 50
atients who underwent ASA reported NSVT in 5 patients
ithin 24 h of their procedure and 1 episode of witnessed
ardiac arrest with documented VF in a patient who later
urvived to ICD implantation (18). Finally, a small study
ublished by Lawrenz et al. (22) reported an 8% annual
ppropriate ICD event rate in 15 post-ASA patients over a
ollow-up period of approximately 3.5 years. This study,
owever, included a significant number of patients with
CD implantation for secondary prevention, with a history
f VT/VF and/or SCD prior to ASA; the event rate in the
rimary prevention group was lower than in the secondary
revention group (5% vs. 10%, respectively).
In our cohort, 9 of 123 patients with an ICD implanted
or primary prevention of SCD had appropriate ICD shocks
ver an average follow-up of almost 3 years. This repre-
ented an overall appropriate ICD discharge rate of 2.8%
er year, which is lower than previous reports in patients
ho underwent ASA (22) and is similar to that reported in
he HCM population who received an ICD for primary
rophylaxis based on SCD risk factors (27,28,39). In one of
hese reports, patients with familial HCM accompanied by
VOT obstruction had a 1.5% rate of SCD annually (37),
hereas another study reported a 5% annual appropriate
CD discharge rate in HCM patients with ICDs for
rimary prevention of SCD (28). In a recently published
tudy with over 500 patients with HCM who underwent
CD implantation for both primary and secondary preven-
ion, the overall appropriate ICD intervention rate was
.5%/year (27). In this study, the primary prevention group
n  383, 76%) had at an appropriate intervention rate of
.6%/year over 5 years.
The presence of individual or multiple traditional risk
actors for SCD in the HCM population were not associ-
ted with an increased rate of appropriate ICD shocks in our
tudy; however, given the low number of events in this
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ICD Therapy After Alcohol Ablation for HCM November 18, 2008:1718–23ohort, this observation must be interpreted with caution.
imilarly, in the recent report of Maron et al. (27) of a large
ohort of HCM patients, no individual risk factor was
ssociated with an increased incidence of appropriate ICD
herapy and the presence of multiple risk factors did not
redict a higher risk of shock.
Interestingly, the patients in this study who received
ppropriate ICD shocks post-ASA did have a significantly
ower LVOT gradient at 3 months post-procedure. This is
ot easily explained, and implies that a reduction in LVOT
radient is not solely responsible for the potential antiar-
hythmic effects of nonsurgical septal reduction. In fact, it
ould suggest that the scar created post-ASA may be
roarrhythmic, but this iatrogenic proarrhythmic effect is
utweighed by a multitude of more beneficial factors,
ncluding reducing septal size, ventricular remodeling, and
ecreasing LVOT gradient.
onomorphic VT after ASA. Several case reports of
ustained monomorphic VT have been published after ASA
or symptomatic HCM (24–26), including 1 patient in this
tudy (26). All 3 reports occurred within 3 weeks of the
SA procedure. None of these patients had a history of
T/VF or significant CAD, and none of the 3 had any
ignificant arrhythmias within 48 h post-procedure. In 2 of
he cases (25,26), slow VT was reported (approximately 150
eats/min) with an exit location near the ventricular septum.
lthough the spontaneous VT morphology reported by
imon et al. (26) was more consistent with an apical free
all exit point, a subsequent electrophysiology study re-
ulted in an inducible monomorphic VT (285 beats/min)
ith a basal septal exit point, more consistent with an
SA-induced scar location. Clearly these reports indicate
hat there is a small incidence of proarrhythmia for VT after
his procedure.
In the present study, 2 of 9 patients with appropriate
hocks had monomorphic VT as the cause of their ICD
hock. Overall, these episodes represent only 1.6% of the
ntire cohort, confirming that monomorphic VT is a rare
ccurrence post-ASA and that scar-mediated re-entry may
ot be a significant long-term complication of this proce-
ure. Presumably the small early proarrhythmic effect of
SA is more than offset by the long-term antiarrhythmic
ffect of this procedure, resulting in a low cumulative
ncidence of ICD shocks.
tudy limitations. This study should be interpreted in
ight of certain methodological limitations. All of the
atients in this study underwent ASA for symptomatic
bstructive HCM; thus, our results cannot be generalized to
he overall HCM population. Additionally, we did not have
control group of patients with ICDs for primary preven-
ion of SCD who did not undergo ASA to compare event
ates, so we can only compare our event rates with historical
egistry and previously published data. We did attempt to
ompare a cohort who underwent ASA and did not receive
CDs to the cohort in this study, but as expected, there were
ertain significant differences between them; namely, the
1roup who received ICDs were perceived to be at higher risk
or SCD (i.e., younger, thicker septums, more risk factors
or SCD). As noted previously, the low numbers of appro-
riate ICD shocks preclude robust analysis of the factors
hat may predict or contribute to these events. Finally, data
egarding inducibility of VT/VF prior to ASA were not
vailable for most patients in this study, although the
redictive value of electrophysiology testing in this popula-
ion is controversial.
onclusions
n summary, the annual rate of appropriate ICD discharges
fter ASA is low and less than that reported previously for
rimary prevention of SCD in a similar population. In fact,
s suggested by previous studies, ASA may reduce VT/VF
y relieving outflow tract obstruction and promoting reverse
emodeling. Although scar-mediated re-entry can occur
fter iatrogenic infarct, it seems to be a rare complication of
his procedure and more than offset by the beneficial effects
f remodeling in the long term. Finally, traditional SCD
isk factors did not predict appropriate ICD shocks in this
ohort.
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